about
Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case reportStimulation of hTAFII68 (NTD)-mediated transactivation by v-SrcPreclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myelomaApoptosis as a tool for therapeutic agents in haematological diseases.Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Histone deacetylase inhibitors: insights into mechanisms of lethality.Potential applications of RNA interference technology in the treatment of cancer.Understanding and exploiting substrate recognition by protein kinases.Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells.NESH protein expression switches to the adverse effect of imatinib mesylate.Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells.Treatment of cockroach allergen asthma model with imatinib attenuates airway responses.Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma.Presentation of extramedullary Philadelphia chromosome-positive biphenotypic acute leukemia as testicular mass: Response to imatinib-combined chemotherapy.
P2860
Q24800045-FC25C200-5149-4890-893B-203371D631DFQ28257266-F6744938-E7B5-414A-9377-CAF76318DD76Q28678660-95D31809-CE22-4E45-8859-B50F02350421Q35684882-BFB24AB1-975C-4338-809A-11CD9CDD2D04Q36158713-D11EEE2B-3EE1-4EED-A959-1CC74FDCBABAQ36219726-AD17A630-DDDF-4E49-AA11-C51B28EE9948Q36429400-FF38D417-5037-4A12-812F-AD8B09D51885Q36631005-990B88A1-38A5-4346-994F-C035066EC40FQ37008882-AB227F51-E660-496A-8C1B-1C2B5F1D795BQ37011627-F10FDA4D-C207-4846-87A4-D3FCE5F34037Q37169157-0E591AD8-2733-4AA4-8D39-78D33AABF944Q39718113-AEA411EB-C542-474E-B90F-44E0BB8DB234Q42337370-935DC2DB-3B9E-480B-82EB-76A0F302A8E8Q45007190-6CF468DD-83C4-4394-A4BF-ACBF057DB971Q45063930-8C65888D-42D0-4ADA-AB14-A9F35E164F3EQ52666713-F33DACE5-4722-4631-B4DB-B98A17E9EF66Q54664160-4EB4E447-2EEB-45DE-AD93-DB180E39D79C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
STI571 as a targeted therapy for CML.
@ast
STI571 as a targeted therapy for CML.
@en
type
label
STI571 as a targeted therapy for CML.
@ast
STI571 as a targeted therapy for CML.
@en
prefLabel
STI571 as a targeted therapy for CML.
@ast
STI571 as a targeted therapy for CML.
@en
P2860
P356
P1433
P1476
STI571 as a targeted therapy for CML.
@en
P2093
Michael J Mauro
P2860
P304
P356
10.1081/CNV-120018235
P577
2003-06-01T00:00:00Z